Quarterly report pursuant to Section 13 or 15(d)

Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)

v3.19.1
Description of Business, Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 3 Months Ended
Dec. 01, 2018
USD ($)
Jun. 01, 2017
USD ($)
Feb. 01, 2012
USD ($)
Dec. 31, 2005
USD ($)
Feb. 28, 2019
USD ($)
Segments
Unit
Feb. 28, 2018
USD ($)
CompensationPlan
Nov. 30, 2018
USD ($)
Debt Securities, Available-for-sale [Line Items]              
Deferred revenue         $ 29,392,197    
Deferred revenue current         8,267,997    
Warranty payment   $ 100,000 $ 75,000 $ 50,000      
Offset personal expenses   10,000          
Commission paid         6,643    
Capitalized contract acquisition costs, net of amortization expense $ 329,231            
Cumulative amortization expense 66,533            
Additional capitalized contract acquisition costs, net of amortization expense         20,954    
Valuation allowance         1,634,000   $ 1,634,000
U.S. Income tax expense (benefit)         $ 105,000 $ 3,203,000  
Income tax expense related to the reduction of the federal tax           2,985,000  
Federal tax rate         21.00%    
Foreign Income Tax Expense         $ 0 0  
Minimum percentage probability of realized tax benefit on settlement         50.00%    
Provisions for interest or penalties related to uncertain tax positions         $ 0 0  
Uncertain tax provisions         0 0  
Impairment on long lived assets         0 $ 0  
Goodwill         1,941,411   $ 1,941,411
Number of employee stock based compensation plan | CompensationPlan           2  
Stock-based option compensation expense         139,000 $ 556,000  
Unrealized holding losses, trading securities           (34,000)  
Unrealized (loss) gain on marketable securities, net of tax           118,746  
Cumulative-effect adjustment from accumulated other comprehensive income to retained earnings         341,000    
Unrealized holding losses, marketable securities         $ (67,000)    
Payment warranty       $ 50,000      
Increased payment warranty   $ 100,000 75,000        
Additional payment warranty     $ 10,000        
Duke University [Member]              
Debt Securities, Available-for-sale [Line Items]              
Asset purchase agrrement closing date         Jan. 31, 2020    
Accounting Standards Update 2014-09 [Member]              
Debt Securities, Available-for-sale [Line Items]              
Incremental contract acquisition cost 329,231            
Reversed incremental acquisition cost 18,408            
ASC 606 adoption adjustment, net of tax 253,447       $ 253,447    
Cumulative effect on retained earnings, tax $ 94,192            
Option One [Member]              
Debt Securities, Available-for-sale [Line Items]              
Contracted storage amortization period         21 years    
Option Two [Member]              
Debt Securities, Available-for-sale [Line Items]              
Contracted storage amortization period         1 year    
Option Three [Member]              
Debt Securities, Available-for-sale [Line Items]              
Contracted storage amortization period         Lifetime    
Contracted storage amortization description         The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women's life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue.    
Previously Reported [Member]              
Debt Securities, Available-for-sale [Line Items]              
Unrealized (loss) gain on marketable securities, net of tax           $ 118,746  
Accounts Receivables [Member]              
Debt Securities, Available-for-sale [Line Items]              
Period of doubtful for accounts receivable due from client         30 days    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member]              
Debt Securities, Available-for-sale [Line Items]              
Number of reportable segments | Segments         3    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]              
Debt Securities, Available-for-sale [Line Items]              
Inventory, in units | Unit         5,974    
Number of units, per month | Unit         12    
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member] | Maximum [Member]              
Debt Securities, Available-for-sale [Line Items]              
Inventory, in units | Unit         144